Navigation Links
Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
Date:11/1/2012

SEATTLE, Nov. 1, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.  OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.  This Phase 1 dose-ranging study is evaluating the drug's safety, tolerability and pharmacokinetics in healthy subjects, and Omeros expects clinical data before year end.

"We are excited that we have begun evaluating OMS824 – our first compound developed entirely in house – in humans," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "Our PDE10 program represents our fourth active clinical program, and the two in Phase 3 trials are poised to read out data this quarter.  We are also continuing to advance our preclinical pipeline, and currently three more programs are slated to enter the clinic in 2013."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition, including schizophrenia and Huntington's disease. Cognitive dysfunction occurs early in these diseases and is responsible for substantial disability. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders, including schizophrenia where OMS824 could also have a beneficial effect on the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of the disease.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of t
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
2. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
3. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
4. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
5. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
6. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
7. Synthetic Biologics Announces $10.8 Million Financing
8. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
9. Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products
10. Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program
11. Law Office of Brodsky & Smith, LLC Announces Investigation of Complete Genomics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys today announced a ... archwire that allows orthodontists to simultaneously apply different forces to different teeth. The ... “We’re thrilled about taking SmartArch one step closer to commercial availability for orthodontists ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... the terms of the agreement, MediVet will acquire the rights to a portfolio ... is currently in pre-clinical development as a potential next-generation treatment for various musculoskeletal ...
(Date:6/29/2015)... June 29, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... "Pete" Petit, has been awarded the Lifetime Achievement Award ... Program. The Entrepreneur Of The Year ...
(Date:6/29/2015)... , June 29, 2015   Veracyte, Inc ... pioneering the field of molecular cytology, today announced that ... Group,s prestigious Top Workplaces list for the second year ... winners based solely on an annual survey of Bay ... honored that the degree to which Veracyte values our ...
Breaking Biology Technology:New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3
... on the path toward making useful superconducting devices has ... nanoscale the realm of billionths of a meter. ... as superconductive transistors and eventually in ultrafast, power-saving electronics. ... Nature, scientists at the U.S. Department of Energy,s ...
... on Strategic Alliances ... ... (TSX: NVN), a company developing innovative therapeutics for,the treatment of viral ... The company also announced that it will,initiate a corporate restructuring that ...
... Oct. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... completed initial scale up of its manufacturing ... scale up of primary production and downstream ... Council Biotechnology,Research Institute (NRC-BRI) located in Montreal, ...
Cached Biology Technology:Scientists engineer superconducting thin films 2Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 2Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 3Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 4Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 5Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 6Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 7Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR 8Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale 2
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
(Date:6/23/2015)... 2015   Valencell, a leader in ... a recent study that illustrates its PerformTek biometric ... activity. In a study conducted at Valencell,s Biometric ... the Apple Watch against a chest strap – ... activity. The study demonstrated that Valencell,s biometric technology ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... KNOXVILLE, Tenn. Consider the case of the ... and in fresh water might appear to be the ... a diverse collection of very specialized individuals. ... variation is the goal of a group of scientists ...
... a defective mitochondrial protein called MCLK1 produce elevated amounts ... yet according to a study in this week,s JBC ... live longer than normal mice. Mitochondrial oxidative stress ... time, reactive oxygen species produced by mitochondria while they ...
... by one of the immune system,s key weapons against infection ... of biliary atresia in infants, a disease where blocked bile ... at Cincinnati Children,s Hospital Medical Center also report that blocking ... lessens damage and may be a way to treat the ...
Cached Biology News:The value of variation: Ecologists consider the causes and consequences 2Scientists link immune system's natural killer cells to infant liver disease 2
... Blood bank refrigerators: ,Each upright ... and superior 4C temperature uniformity for refrigerated ... HemaPro 2000 Surveillance Module for complete blood ... BBR37 are equipped with the HemaPro 101 ...
Sterile, individually wrapped, 4mm Cuvettes...
... an enhanced form of Tobacco Etch Virus ... active, and significantly more stable than native ... Protease specifically recognizes a seven amino acid ... it useful for removing affinity tags from ...
... The LCMS-2010EV is a fully flexible quadrupole ... conventional HPLC, high-speed HPLC, 1-D and 2-D ... scale separations. It incorporates a drying gas ... for high sensitivity, especially for low-to-medium polarity ...
Biology Products: